27/03/2020
Marie Skłodowska-Curie Actions

Postdoc candidate for a MSCA IF in Human Parkinson`s disease patient specific brain organoids for phenotyping and drug development

This hosting has expired


  • OFFER DEADLINE
    15/05/2020 23:30 - Europe/Brussels
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • LOCATION
    Luxembourg, Esch-sur-Alzette
  • ORGANISATION/COMPANY
    OrganoTherapeutics (application management through Luxinnovation)

OrganoTherapeutics is interested in hosting a postdoctoral fellow within the Marie Skłodowska-Curie Individual Fellowship programme. 

 

         Please note that this opportunity is not a funded positions (yet); it depend on

         1. The organization selecting you for continuing the process and

         2. A successful proposal written mostly by you (with some input from your host organization           in Luxembourg) and submitted before September 9th 2020.

 

 

Project idea: 

We are looking for candidates who are interested in working on a project which is centred around the usage of human Parkinson`s disease patient specific brain organoids for phenotyping and drug development. Depending on the preferences of the candidate, this project could be either more focused on cell culture work or on computational data analysis and modeling.

 

Offer Requirements

  • Profile 1: Consolidated experience in the work with human cell cultures. Desirable would be work with organoids, high content imaging or drug development.
  • Profile 2: Experience in image analysis, computational data analysis and modeling, machine learning / artificial intelligence approaches for data analysis.

 

Institute description: 

OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary human-specific mini-brains which represent a model mimicking faithfully the human Parkinson’s disease pathology. Next to in vitro cell culture approaches, we strongly rely on machine learning and artificial intelligence methods for data analysis. OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease, which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.

 

Benefits

A successful candidate will have the offer to advance in the company and gain more responsibility over time. We offer an attractive incentive scheme.

 


 

About Marie Skłodowska-Curie Actions Individual Fellowship:

The MSCA IF are postdoctoral fellowships, financed through the European Commission for 2 year positions, covering salary and research costs of the researchers, who can come from anywhere in the world. The evaluation process of these programmes is more about the project and the career development of the candidate, than his/her publication record. The organizations in Luxembourg that want to host such talented researchers include large public research organizations as well as private companies that offer interesting job perspectives after completion of the fellowship.

Minimal eligibility criteria

  • Individual: applicant applies together with host institute
  • PhD at the deadline or Masters plus 4 years of full time equivalent research experience
  • Not working or living in Luxembourg for longer than 12 months before the call deadline
  • For rules see here or contact your NCP

 

How to apply

Please submit your CV to Charles Betz, Advisor - European R&D and Innovation Support at Luxinnovation, until May 15th 2020 and refer to which position(s) you are applying for; you can also send several finetuned CVs if you are interested in multiple positions. Make sure you address the text and requirements mentioned by the respective hosts. 

Please note that applications are made through Luxinnovation, your contact point for Horizon 2020 in Luxembourg, before being handed over to the host company.

 

Luxinnovation, the Luxembourgish Innovation agency and National Contact Point for MSCA, will support both you and your future host institute during your application phase. For all applicants coming to Luxembourg we offer guidance documents, webinars, training in proposal writing and we will review your proposals if you wish so (depending on our availability). In 2019, MSCA IF proposals from Luxembourg had an average success rate of 28.5%, and proposals reviewed by our service 42%.

More information can be found on our website.

 

  • Cell culture
  • Stem cells
  • Organoids
  • Drug development,
  • High content imaging
  • machine learning
  • artificial intelligence
  • computational modeling
 

 

Disclaimer:

The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.